The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.

BACKGROUND Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor. We assessed the effects of GM1 on the prevention of TIPN in breast cancer patients. METHODS We conducted a randomized, double-blind, placebo-controlled trial including 206 patients with early-stage breast cancer planning to receive taxane-based adjuvant chemotherapy with a follow-up of more than 1 year. Subjects were randomized to receive GM1 (80 mg, Day -1 to Day 2) or placebo. The primary endpoint was the Functional Assessment of Cancer Treatment Neurotoxicity (FACT-Ntx) subscale score after 4-cycles of chemotherapy. Secondary endpoints included neurotoxicity evaluated by CTCAE Version 4.0 and the Eastern Cooperative Oncology Group neuropathy scale (ENS). All statistical tests were two-sided. RESULTS In 183 evaluable patients, GM1 group reported better mean FACT-Ntx subscale scores than patients in the placebo group after 4-cycles of chemotherapy (43.27 [95% CI = 43.05 to 43.49] vs 34.34 [95% CI = 33.78 to 34.89]; mean difference = 8.96 [95% CI = 8.38 to 9.54], P < .001). Grade ≥ 1 peripheral neurotoxicity in CTCAE v4.0 scale was statistically significantly lower in GM1 group (14.3% vs 100.0%, P < .001). Additionally, GM1 group reported a statistically significantly lower incidence of grade ≥ 1 neurotoxicity assessed by ENS sensory neuropathy (26.4% vs 97.8%, P < .001) and motor neuropathy subscales (20.9% vs 81.5%, P < .001). CONCLUSIONS The treatment with GM1 resulted in a reduction in the severity and incidence of TIPN after 4-cycles of taxane-containing chemotherapy in patients with breast cancer.

[1]  L. Minasian,et al.  Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715) , 2018, Journal of the National Cancer Institute.

[2]  T. Julian,et al.  Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30 , 2018, Journal of the National Cancer Institute.

[3]  G. Cavaletti,et al.  PERIPHERAL NEUROPATHIES: Chemotherapy‐induced peripheral neurotoxicity: management informed by pharmacogenetics , 2017 .

[4]  N. Lunet,et al.  Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study , 2016, Supportive Care in Cancer.

[5]  S. Scarpa,et al.  Taxane induced neuropathy in patients affected by breast cancer: Literature review. , 2015, Critical reviews in oncology/hematology.

[6]  M. Ewertz,et al.  Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. , 2015, European journal of cancer.

[7]  Dawn L Hershman,et al.  Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Schwarz,et al.  The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions , 2014, Neuropharmacology.

[9]  M. Koltzenburg,et al.  Chemotherapy‐induced peripheral neurotoxicity: A critical analysis , 2013, CA: a cancer journal for clinicians.

[10]  G. Hortobagyi,et al.  Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Speck,et al.  Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. , 2013, Journal of oncology practice.

[12]  C. Shapiro,et al.  Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. , 2013, JAMA.

[13]  S. Jiao,et al.  Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors , 2013, World Journal of Surgical Oncology.

[14]  P. Novotny,et al.  Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy , 2012, Cancer.

[15]  K. Fouad,et al.  Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice , 2012, Proceedings of the National Academy of Sciences.

[16]  P. Novotny,et al.  Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Antai Wang,et al.  Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy , 2011, Breast Cancer Research and Treatment.

[18]  G. Cavaletti,et al.  Chemotherapy-induced peripheral neurotoxicity , 2010, Nature Reviews Neurology.

[19]  J. Schneider,et al.  GM1 ganglioside in Parkinson's disease: Results of a five year open study , 2010, Journal of the Neurological Sciences.

[20]  A. Valachis,et al.  Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. , 2010, Cancer treatment reviews.

[21]  Sudhakar Tummala,et al.  NCCN task force report: management of neuropathy in cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  P. Mantyh,et al.  The Paclitaxel Acute Pain Syndrome: Sensitization of Nociceptors as the Putative Mechanism , 2007, Cancer journal.

[23]  H. Mouridsen,et al.  Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Cella,et al.  Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study , 2006, International Journal of Gynecologic Cancer.

[25]  S. Swain,et al.  Peripheral neuropathy induced by microtubule-stabilizing agents. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Ohgami,et al.  Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. , 2006, Diabetes.

[27]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Fishman,et al.  Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[29]  David Cella,et al.  Measuring the side effects of taxane therapy in oncology , 2003, Cancer.

[30]  J. Chang,et al.  Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. , 2000, European journal of cancer.

[31]  E. Mamounas,et al.  Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Y. Fang,et al.  The Role of GM1 and Other Gangliosides in Neuronal Differentiation Overview and New Findings a , 1998, Annals of the New York Academy of Sciences.

[33]  H. Gogas,et al.  The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. , 1996, Gynecologic oncology.

[34]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[35]  M. Hamaguchi,et al.  Ganglioside GM1 binds to the Trk protein and regulates receptor function. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Schneider,et al.  Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. , 1992, Science.

[38]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[39]  R. Brady,et al.  Biosynthesis and function of gangliosides. , 1976, Science.

[40]  S. Mabuchi,et al.  Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients. , 2015, Anticancer research.

[41]  T. Huanmanop,et al.  Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. , 2009, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[42]  J. Manfredi,et al.  Taxol: an antimitotic agent with a new mechanism of action. , 1984, Pharmacology & therapeutics.